This article is by Ann Fordham and Martin Jelsma, and is republished from openDemocracy. It is part a series of articles about this April's UNGASS. Further information appears below.

In April 2016, the UN will dedicate, for the third time in its history, a United Nations General Assembly Special Session (UNGASS) to discuss global drug policy. The UNGASS has the potential to be a ground-breaking moment that could change the course of the international drug control system. However, political divisions and entrenched institutional dynamics have dampened hopes that it will go down in history as the beginning of the end of the war on drugs.

Conventional drug control wisdom has put forward the view that stopping the supply of drugs at the source would solve the 'world drug problem', but Latin American countries bear witness to the failure of this approach. Stirred into action by the futility of spending billions of dollars to fight an unwinnable and increasingly violent war on drugs, it is no surprise that political leaders from Latin America have been at the forefront of the drug policy debate. From their perspective, the high human cost in terms of violence, insecurity, mass incarceration and the exacerbation of the social and economic vulnerability of some of society’s most marginalised groups – can no longer be justified as necessary collateral damage in pursuit of eradicating drug markets.

A growing group of Latin American and Caribbean countries are calling for a real discussion on alternative policies. In the meantime, Uruguay has moved to create the world's first national legally regulated cannabis market for recreational use, and similar initiatives have happened in the US at the state level. This opening up of the long entrenched and seemingly immovable discussion on prohibitionist drug control principles is unprecedented and has implications for global policy.

In this context, the UNGASS in April represents a critical juncture, an opportunity for an honest evaluation of global drug policy and how to address the most pressing challenges going forward. Secretary General Ban Ki-moon, in recognition of this rare and important opportunity, has urged member states to use the 2016 UNGASS "to conduct a wide-ranging and open debate that considers all options."

The UNGASS preparations

The initial discussions to prepare for the UNGASS were fraught with disagreements over many procedural aspects. These included difficult negotiations over the extent to which the UN Commission on Narcotic Drugs (CND) in Vienna would lead the process; how to strike the right balance between the UN capitals of Vienna, Geneva and New York in the preparations; how to ensure meaningful involvement of all relevant UN agencies, academia and civil society; and – last but not least – how open the debate should be: should it be restricted to a discussion of how to improve the implementation of the 2009 Political Declaration and the achievement of its targets for 2019, or should the UNGASS be an opportunity to challenge the current global drug control strategy, possibly even questioning its foundation of the three UN drug conventions?

These difficult negotiations, which on the surface often appeared to be arguments over procedure, reflected the deep political divisions within the international drug policy debate. The much-revered 'Vienna Consensus' continues to weaken as the divide between some governments becomes increasingly irreconcilable. A growing number of countries now believe that the traditional repressive drug control approach, based on zero-tolerance, has not worked and has led to disastrous consequences for human rights, public health, citizen security and sustainable development, and as a result it has to be modernised.

Some countries calling for an open and inclusive debate at the UNGASS questioned whether this could be truly achieved with a process led by the Vienna-based drug control apparatus, given that the CND, the UN Office on Drugs and Crime (UNODC) and the International Narcotics Control Board (INCB) have all gained quite a conservative reputation over the decades. Conducting all the preparations in Vienna led to a further problem for inclusivity, given that at least 70 member states do not have permanent representation there and would therefore struggle to fully participate in the process. The point of convening an UNGASS, is that by definition all UN member states and the whole UN system should be included on a equal basis, but limiting the political negotiations on the outcomes exclusively to Vienna, means that in practice the countries and UN agencies not represented in Vienna have much less influence on the process.

In the end, the hard fought-over resolution on the procedures decided that the UNGASS "will have an inclusive preparatory process that includes extensive substantive consultations, allowing organs, entities and specialized agencies of the United Nations system, relevant international and regional organizations, civil society and other relevant stakeholders to fully contribute to the process", while the CND "as the central policymaking body within the United Nations system dealing with drug-related matters, shall lead this process", inviting the president of the General Assembly to "support, guide and stay involved in the process".

UN special sessions are rare and crucial moments in UN-level policy making and are designed to ensure a coherent UN system-wide response to global problems of major concern to the international community. This has so far been less than optimal in discussions on global drug policy. After initial slow engagement from other key UN agencies, significant contributions have now been made from UNDP, UNAIDS and the WHO. The Office of the High Commissioner for Human Rights has also submitted a comprehensive reportthat outlines the most pertinent human rights violations in relation to drug control policies, while the Human Rights Council held a high level panel in September 2015 on the topic of "the impact of the world drug problem on the enjoyment of human rights".

A Civil Society Task Force (CSTF) was convened to ensure the participation of civil society in the process. The CSTF has representatives from every region of the world, as well as representatives of the key affected populations such as people who use drugs and subsistence farmers growing drug-linked crops among others. Initially, formal recognition of the CSTF was challenging – civil society has always had to fight for visibility and access at the CND but over the last year there has been increasing support for this initiative from governments.  A major victory for the CSTF was explicit support from the president of the General Assembly, who presided over an Informal Interactive Stakeholder Dialogue in New York on the 10 February 2016 organised with the CSTF in support of the preparatory process. The calls for progressive policiesbased in principles of harm reduction, of public health and of human rights from global civil society were deafening at the event.

Shifting regional priorities

In terms of regional perspectives, as noted above, the impetus for pushing for another UNGASS on drugs followed growing calls for reform from across Latin America at the highest political level. In fact, the previous UNGASS meetings in 1990 and 1998 had been convened in response to similar calls from Colombia and Mexico. Around them, a group of like-minded countries is gradually shaping up around certain positions, including Ecuador, Uruguay and Costa Rica and supported by Brazil and Bolivia on some issues. Caribbean countries have long been largely absent from the debate, not least because discussions have been limited to the CND in Vienna, where few Caribbean countries are represented – although Jamaica has recently joined the chorus of dissent and the discussion on several other islands has intensified.

In terms of European, particularly European Union (EU), engagement, this has been markedly different from Latin America and reflects the fact that Europe has managed to avoid the sharpest edges of a repressive approach to drug control. European countries have not experienced to the same extent, the high human cost in terms of violence, insecurity, and mass incarceration experienced in Latin America.  Of course the context is different, but in addition, many European governments have been pragmatic, have prioritised health care, harm reduction and human rights protection. While in Europe there are some serious issues regarding the criminalisation of people who use drugs and disproportionate sentences for minor drug offences, most European countries have managed to keep a certain distance from the escalation of the war on drugs in the 1980s and 1990s in the US, Latin America and Asia. At the international level, the leadership that EU governments have shown in this regard has been critical in shifting the drug policy narrative towards public health, harm reduction and human rights principles.

On issues where common positions can be found, the EU can have a strong impact on the global debate. For example, a united EU promoted the principle of proper sequencing with respect to ensuring that subsistence farmers have sufficient access to alternative livelihoods before being forced to abandon their drug-linked crops. The EU has also demonstrated unity and commitment on harm reduction and the removal of death penalty for drug offences, although a global consensus on these issues is not yet in sight.

Unfortunately, there are also crucial areas where a strong European voice has been absent, and the EU has failed to understand or acknowledge the sense of urgency and relevance of this UNGASS. This is clearly the case with regard to the shift in priority that Latin American countries are seeking, to move away from arresting small-time dealers and chasing drug shipments towards reducing drug-related violence, organised crime and corruption instead. In a sense, this is a plea for a harm reduction policy on the supply side: the drugs market will not be “eliminated or significantly reduced” by 2019, and it is time to forget the hollow illusion of a drug-free world.

Instead, government policy could be more sophisticated and focus on mitigating the most harmful aspects of the drug trade through reducing the levels of illicit drug market-related violence, crime, insecurity and corruption. This thinking mirrors similar priority shifts that have previously taken place in Europe under the harm reduction banner, with governments taking a pragmatic approach to reduce the harms associated with drug consumption without necessarily seeking to stop the use of drugs. These harm reduction policies and programmes have significantly reduced drug-related harm such as overdose deaths, and HIV and hepatitis C prevalence among people who inject drugs.

Cannabis policy and UN treaties

Another example is the lack of EU engagement in the debate about global cannabis policy developments, the result of the absence of a common EU position on cannabis and huge national policy variations. Demonstrating an ostrich-like denial regarding cannabis policy developments in the Americas but also at local levels within the EU, the EU common position for the UNGASS underscores the need to “maintain a strong and unequivocal commitment to the UN conventions” and that there is “sufficient scope and flexibility within the provisions of the UN Conventions to accommodate a wide range of approaches to drug policy”. In addition, the issue of drug control is a low political priority as the EU currently has it hands full with the refugee crisis and existential threats around the euro and the future of European integration.

A game-changing difference between this UNGASS and the preceding ones is the fact that the position of the US has fundamentally changed. No longer among the hardliners, the US has acknowledged, both at the UN but also more recently domestically, that the over-reliance on incarceration has failed. In August 2013, US Attorney General Eric Holder admitted that mandatory minimum sentences for drug offences were ‘draconian’ and that too many Americans had been imprisoned for too long for no good law enforcement justification. He made it clear that the status quo was unsustainable and damaging. In 2015, President Obama began a process to commute the sentences of around 6,000 federal drug offenders. In early 2016 the congressional task force created to examine overcrowding in the federal prison system, recommended the repeal of federal mandatory minimum sentences for drug offences. Different legislative initiatives have been tabled, including the Smarter Sentencing Act, which would cut many mandatory minimums for drug offences in half.

The domino effect of cannabis regulation at state level makes the US less sure-footed of condemning other countries for not stringently adhering to a zero-tolerance approach. Cannabis regulation for recreational use is outside of the scope of the current UN treaty framework for drugs, creating a significant problem for the US since it undermines its credibility to continue defending the conventions as they stand. The big question is whether this will lead to the US accepting more flexibility in policy areas that have been explored elsewhere. These include initiatives such as decriminalisation, drug consumption rooms or the regulation of coca in Bolivia, all policy options that the US currently opposes.

UNGASS outcomes: change of course

The past several years have seen significant changes in the global drug policy landscape representing a trend towards more humane and proportional responses based on health, human rights and development principles. To some extent, the UNGASS will acknowledge those advances and thereby consolidate the significant change of course that is happening in various regions of the world. Perhaps the most significant advance will be on the issue of access to controlled medicines – an area that has long been de-prioritised in favour of a focus on repressive, law enforcement-led approaches to reduce the illicit drug trade. Most drugs included in the schedules of the UN conventions also have important medical purposes, and several appear on the WHO “List of Essential Medicines”.  However, the availability of opiate painkillers like morphine for example, has been dramatically low in most developing countries due to overly strict regulations reflecting over-riding concerns about diversion and addiction rather than a need to ensure access to pain relief.

Unfortunately, other areas of progress remain stilted. Russia, alongside several Asian and Middle Eastern countries, has played hardball in the negotiations, effectively putting the brakes on the shifting discourse. The negotiations are driven by consensus, making it unlikely that contested policies in the field of harm reduction, or reforms like decriminalisation, despite being widely accepted and propounded by all relevant UN agencies, will be explicitly recommended in the UNGASS outcome document. Likewise, a clear condemnation of the death penalty for drug offences is probably going to be blocked by a small group of countries. The prophecy that allowing the CND to take full control over the UNGASS preparations would undermine progress towards a more system-wide coherent UN drugs policy seems to be being borne out. Negotiations about the UNGASS outcomes have taken place mostly in ‘informal’ sessions in Vienna, dominated by a minority of member states and from which civil society is excluded from participating or even observing.

For the General Assembly, an obvious priority for this UNGASS would be how to align UN drug policy with the recently adopted new global framework of the Sustainable Development Goals (SDGs), but negotiations in Vienna carry on as if they are negotiating another CND resolution. Submissions from other member states, UN agencies and civil society calling for a recognition of the failure of repressive responses and highlighting the need to connect the drugs issue with the agreed UN priorities for the future of the planet have so far not been reflected in successive drafts of the UNGASS outcome document.  The general tone of these drafts is very much ‘business-as-usual’.

At present, few countries are willing to openly acknowledge the existence of structural deficiencies with regard to UN system-wide coherence, the institutional architecture and the legal treaty framework. No easy solutions are available for reforming the foundations of the global control system and consensus will be hard to find, but a continued denial of the reality of the on-going policy trends and the resulting tensions with the treaty system will not make them disappear. In fact, to do so will hinder the much-needed evolution of the UN drug control system and its ability to adapt to the realities of today. Towards this end, it could be helpful if the UNGASS outcome leads to the convening of an advisory group or an expert panel to think through different scenarios for the future evolution of the system, especially in the lead up to the next important moment in 2019 when member states will have to agree a new global action plan on drugs, hopefully more in line with the broader set of UN priority goals for the next decade.

Although it is clear that the so-called ‘Vienna consensus’ has been breaking apart for some time and there is a growing desire to find viable policy alternatives to repression and punishment, there are still powerful countries and entrenched bureaucracies that are staunchly opposed to any kind of reform. The divisions between member states but also between UN agencies on this issue have become too visible to ignore and the UNGASS is a perfect opportunity for an honest assessment of the performance of the international drug control system and the options for a change of course.

Given the high human cost of the damaging approaches pursued to date, many people around the world have high hopes that governments will not squander this opportunity. And yet, to what extent the UNGASS can really live up to these hopes remains to be seen. The latest dynamics in Vienna do not bode well, as bureaucratic machinations, political complacency and exclusion seem to rule the process. The lack of vision, inclusivity and commitment to finding new solutions to many of the challenges that remain must be strongly condemned, especially given the urgency expressed by those countries that called for this moment in the first place.

This article was written by Ann Fordham of the International Drug Policy Consortium and Martin Jelsma of the Transnational Institute. It is published as part of an editorial partnership between openDemocracy and CELS, an Argentine human rights organisation with a broad agenda that includes advocating for drug policies respectful of human rights. The partnership coincides with the United Nations General Assembly Special Session (UNGASS) on drugs.